This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)

'CT-P59 is a monoclonal antibody targeted against SARS-CoV-2 spike receptor binding protein as a treatment for SARS CoV 2 infection. CT-P59 is currently being developed by the Sponsor as a potential treatment for SARS-CoV-2 infection. In this study, safety, tolerability and virology of CT-P59 will be evaluated in patient with mild symptoms of SARS-CoV-2 Infection.

Inclusion criteria

Each patient must meet all of the following criteria to be randomized in this study:

• Adult male or female patient, aged between 18 to 60 years (both inclusive).
• Patient with laboratory confirmed SARS-CoV-2 infection by Reverse Transcription Polymerase Chain Reaction (RT-PCR) at Screening.
• Patient has mild conditions meeting all of the following criteria:

• Oxygen saturation ≥ 94% on room air.
• Not requiring supplemental oxygen.
• Onset of symptom is no more than 7 days prior to the study drug administration.

Exclusion criteria

• Patient with severe condition meeting one of the following:

• Respiratory distress with respiratory rate ≥ 30 breaths/min.
• Requires supplemental oxygen.
• Experience shock.
• Complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion.
• Any other conditions suspected of being severe symptoms of SARS-CoV-2 infection, in the opinion of the investigator, including but not limited to radiographic findings in lung.